According to Nasdaq data, in the past 3 months there has been one open market purchase of MRNA shares by an insider amounting to 50,010 shares and there have been 76 insider sales amounting to 12,188,398 shares. [14], Afeyan cofounded Moderna Therapeutics with Kenneth Chien of Harvard University and the Karolinka Institutet, Robert Langer of the Massachusetts Institute of Technology, and Derrick Rossi of Boston Childrens Hospital. Flagship has shut down four companies in which it invested $10 million or more, as well as 13 early-stage startups in which it had invested less than that amount. In 2016, Stphane Bancel said, Advancing to the clinic certainly was the most gratifying milestone. ( 25, 1962 [1], , ), , Flagship Ventures [2] . Today, the company has approximately 820 full-time employees and a market capitalization of about $28 billion. [30] It includes The 100 Lives initiative, which celebrates survivors and rescuers of the Armenian genocide,[15][2] and the Aurora Prize for Awakening Humanity, an annual award given to an individual (and an affiliated organization) who has faced personal risk to enable others to survive since 2016. What if red blood cells could transport drugs along with oxygen? Noubar Afeyan is the founder and CEO of Cambridge, Mass. Moderna Inc. was founded over four decades later, in 2010 in Cambridge, Massachusetts ( here), by Derrick Rossi, Robert Langer, Kenneth R Chien, and venture capitalist Noubar Afeyan ( here, here . If I had thought about it a lot, I am very sure I would not have started a company. Reflecting on his career trajectory, he realized that being an immigrant has had a significant influence on his path. Noubar Afeyan, co-founder and chairman of Moderna. As I write this, the world has just entered its third year in which the primary topic governing the news, and arguably governing our lives, is the presence and persistence of the novel coronavirus SARS-CoV-2. This letter explores four of the forces shaping biotechs future: programmable medicines and digital biology; machine learning and artificial intelligence; the exponential value potential of bioplatforms; and a pandemic-inspired regulatory reset. on track to return investors money 15-fold. Id like to say I would have predicted it, but I would not have, said Fauci, who has often said he would have been satisfied with Covid vaccines that were 70% or 75% efficacy. Perhaps a second question for all of us in and beyond biotech to take into 2022 is: What Now? Between 2011 and 2017, Moderna raised $2 billion in venture capital funding.. Still, Moderna co-founder Noubar Afeyan understands the hesitation to get a new vaccine. I have often asked why we expect extraordinary breakthroughs from reasonable people doing reasonable things. Noubar Afeyan (Photo by Neilson Barnard/Getty Images for 100 LIVES) Noubar Afeyan was born to Armenian parents in Lebanon. On the one hand, 2021 was an extraordinary year for life science investment, with several chart-topping raises by early-stage companies. Afeyan says his goal is simply to help people, and he credited his drive and passion for philanthropy to his immigrant mentality. Far superior ways to engage, involve and empower citizens to improve their own health will be central to a preemptive medicine paradigm precisely because the absence of symptoms means that participation is a choice, rather than a compulsion to alleviate pain or discomfort. Noubar invented the model, if you will, and essentially trained us in doing this.. (Read full essay here). Building a startup is always an iterative process. "[2] According to the company website, Flagship Pioneering has "fostered the development of more than 100 scientific ventures resulting in $30 billion in aggregate value, thousands of patents and patent applications, and more than 50 drugs in clinical development. He has been completed his graduation from McGill University and has completed his PhD in Biochemical Engineering in 1987. We now know what is possible when regulatory authorities operate with urgency and balance societal risk with societal benefit. To support the global scaling of breakthrough innovation to preempt and address fundamental human and planet health challenges, the Goldilocks regulatory framework for life sciences should aspire to be as innovative as the science it is regulating and as bold as the problems the innovation is looking to address. I constantly say things that are unreasonable and seemingly crazy, says Noubar Afeyan, founder of venture firm Flagship Pioneering and chairman of Moderna. The companies said they will file for an emergency use authorization with the Food and Drug Administration in the coming weeks, and will file with other global regulators. Packard, who died in 1996, described himself as a new breed of engineer, a blend of entrepreneur and innovator. He starts with those what-if questions. During his 30-year career as inventor, entrepreneur and CEO, Dr. Afeyan co-founded and helped build over 40 successful start-ups. He was an outlier then, he says, as both a young founder and an immigrant, at a time when neither was an advantage. The record shows immigrants and immigrant-led companies created the vaccines. This is an archived article and the information in the article may be outdated. Highly Skilled Immigrants Drive U.S. Preemptive medicine can prevent or delay the onset of disease using new and emerging tools to detect pathways toward disease and interrupt those pathways, helping us individually and collectively to be more resilient in the face of infectious disease. What if not all viruses were bad? In June, Flagship raised $3.4 billion for a new fund, a giant pool of money even at a time when investment has been flowing to biotechnology and therapeutics. [21], Afeyans awards include the Ellis Island Medal of Honor,[22] an award granted to outstanding Americans who have distinguished themselves as U.S. citizens, and who exemplify outstanding qualities in both their personal and professional lives, while continuing to preserve the richness of their particular heritage. When world powers step in to stop unfolding atrocities, it sends a signal to aggressors that annexing land or destroying a people and culture will not be tolerated," he wrote. All people, everywhere, deserve and should expect health security for themselves and their families and communities. Whats outside that is where people think it is reckless to work, he says. He was always having to prove himself, says Afeyan. By. [12] Joule's technology has been scaled to a demonstration facility,[13] and the company has announced a commercial partnership with Audi. Other immigrants in key leadership positions at Moderna include Chief Medical Officer Tal Zaks, in charge of clinical development at the company. June 21st, 2021, 12:21 PM PDT. He's also the chairman and cofounder of biotech firm Moderna, known for its Covid-19 vaccine which was authorized by the U.S. FDA in December 2020. It raised $1.1 billion, a huge sum for an agricultural startup, but has struggled to get its operations on track. The crisis has thrown into relief the powerful forces shaping our industry, and those forces, taken together and furthered by innovation, capital, and talent, make it possible to totally rethink how we define and approach illness and disease, and protect and prolong our health. In 2000, he started Flagship Pioneering to create and fund startups in health care and sustainability. While Moderna is by far its largest, other publicly traded graduates include Denali Therapeutics (market cap $6.3 billion), which is working on treatments for neurodegenerative diseases; Quanterix (market cap $2.1 billion), which makes tools to measure proteins for disease detection and treatment; and Rubius (market cap $1.3 billion), which uses red blood cells as treatments for cancer and autoimmune diseases. How will we the survivors better the world with the new knowledge and innovation that has emerged through the necessity of crisis? As my colleagues Stephen Berenson and Andy Oh explain: Bioplatforms have several advantages. When the immune system sees these fragments, it learns how to attack them. Noubar Afeyan is founder and CEO of Flagship Pioneering. The work in the microbiome, in part, led to more recent work on viruses as Afeyan and his team questioned whether there are viruses in our bodies that arent pathological. Born in Beirut, Lebanon, in 1962 to Armenian parents, he and his family fled the Lebanese Civil War to move to Montreal in 1975. But Afeyan wondered if he could create a structure to start multiple companies at one time, always having multiple early-stage ideas and potential startups percolating in the labs. As the firms researchers explore ideas, theyll change their approachor even what theyre working onwith little regard for how the outside world might view such seeming flip-flops. Afeyan is of Armenian heritage and was born in Beirut, Lebanon. In 2000, Afeyan founded Flagship Pioneering to create and fund early-stage start-ups addressing unmet needs in healthcare and sustainability. Flagship Pioneering Founder and CEO and Moderna Co-founder and Chairman Dr. Noubar Afeyan presents at the 2022 Code Conference.Subscribe: https://goo.gl/FRle. Innovation, Report Shows, Entrepreneurship: Kill The Myth, Follow The Science, 2022 Billionaires: Cities With The Most Billionaires, The Billionaire Chairman Of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship, Forbes Releases 40th Annual Forbes 400 Ranking Of The Richest Americans, Surging Moderna Stock Mints The Vaccine Makers Fifth Billionaire, Flagship Pioneering, The Investor Behind Moderna, Raises $3.4 Billion For New Fund, VC Firm Of Moderna Chairman Sold $1.4 Billion Of Stock In Two Months, Moderna Cofounder Noubar Afeyan On Innovating To Drive Real Change, Trump Takes Credit For Vaccine Created By Others, Including Immigrants. [12][13], Afeyan has authored numerous scientific papers. Moderna co-founder and chairman Noubar Afeyan an American entrepreneur of Armenian descent has made to this year's Forbes list of the 400 richest people in the United States. [5][7][3] He graduated from Loyola High School in Montreal in 1978. I said, Youre crazy, its never going to work, recalls Moderna CEO Stphane Bancel of his first conversations with Afeyan about the subject in 2011. In 2007, Afeyan and David Berry (inventor) co-founded Joule Unlimited, which is developing Solar Fuelsdrop-in fuels produced directly from the sun. Francine Lacqua speaks with Moderna co-founder Noubar Afeyan about his path to success, the promise of mRNA technology and the coronavirus vaccine. Flagship Pioneering, the investor behind Covid-19 vaccine maker Moderna, said today that it had raised $3.4 billion for a new fund. Since the advent of modern medicine we have focused more on treating the symptoms we can see and measure than on addressing the underlying disease. The keynote speaker of the evening was Dr. Afeyan. In its final accounting, this pandemic will likely log a death toll that far surpasses the mass casualties of the genocides and holocaust of the past century. In 2000, Afeyan founded Flagship Ventures (renamed Flagship Pioneering in 2016), where he currently serves as Senior Managing Partner and CEO. document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() ); Copyright 2023 Nexstar Media Inc. All rights reserved. His family moved to Montreal, Canada in 1976. 1. Flagship is a venture capital firm with a total of $17 billion in assets that operates more like an incubator. [3][1] By 2020 Afeyan had co-founded and developed 41 start-ups. Noubar Afeyan is the founder and CEO of Cambridge, Mass. Moderna just wrapped up the third phase of clinical trials and is awaiting approval from the Federal Drug Administration. At the age of 13, he immigrated with his family to Canada and attended [], Ph.D, Massachusetts Institute of Technology; Bachelor of Science, McGill University. Its a technology that could potentially give us a vaccine within a year from now., The new approach Im most excited about is known as an RNA vaccine, wrote Bill Gates in theWashington Post. Like many Armenians, Noubar Afeyan's family moved from country to country, trying to find a safe haven. Theres also a structure to how Flagships researchers consider dozens of ideas, accepting some and rejecting others. fast-tracks health care innovations, says Moderna's chairman. Dr. Noubar Afeyan is founder and CEO of Flagship Pioneering, a company that conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. November 9, 2021, 8:30 AM PST. Board Director. (Read full essay here). There were only five infections in patients who developed Covid-19 after receiving Modernas vaccine, mRNA-1273. Just as there is little gained from healing an organ inside a dying body, prolonging human health and longevity wont matter without a healthy planet to call home. They have four children. We know how quickly new therapies can be tested, approved, and scaled. That feeling of restarting turns out, is very similar to what you need to have a startup of a company or to innovate.. . Modernas Chief Technical Operations and Quality OfficerJuan Andres immigrated from Spain. The prospect that I wouldve been throwing away a brand-new Ph.D. going into an area that wouldve failedthat thought never occurred to me.. The company launched from Flagship Pioneerings innovation foundry, VentureLabs, in 2010. It has been called Dr. Seuss Day because of this. In the opposite direction, we have only scratched the surface in terms of leveraging biology to advance AI research. For Afeyan, though, the hope is that Moderna isnt a one-off stratospheric success, but just one of dozens of companies that could break out from the work hes been doing at Cambridge, Mass.-based Flagship for the past two decades. Unfortunately, we are not yet in the pandemics wake: We remain in its grasp. Flagship companies such as Generate Biomedicines and Cellarity are creating programmable medicines in the realm of proteins/antibodies and small molecules, respectively, where the programming code to create the right protein for the right target, or the right small molecule to get the right cellular biology, is elucidated and leveraged. He was born to Armenian parents in Lebanon and immigrated with his family in his early teens to Canada. From the terrorist attacks of 9/11 emerged a major reorganization and consolidation of certain government agencies and functions, and a fundamental relook at everything from how we monitor the movement of money to how we screen airline passengers. He was not from the country. The Afeyans had a business exporting eggs from Turkey to Bulgaria and some family members moved to Bulgaria after 1918. This remains a long game, however, as researchers work out the science and go through clinical trials. Moderna was the first to invent the field of mRNA for therapeutics, even before the pandemic hit. "We agree vaccines ought to be free. We knew that generating an immune response against this protein would prevent the virus from infecting the cells. He is also on the board of the MIT Corporation. He said changes to DNA can be essentially permanent, like hardware. If the idea proves out in the lab, Flagship gives the new company a name and commits $20 million or more to it as a wholly owned subsidiary. Unlike a flu shot, which contains fragments of the influenza virus so your immune system can learn to attack them, an RNA vaccine gives your body the genetic code needed to produce viral fragments on its own. (Source: Bloomberg) Thats where we stand, were very excited.. A.I. He lectures in the United States and internationally on topics ranging . [2] After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he became Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics.[4]. Noubar has to find the way increasingly to figure out how to run a bigger organization and keep his finger on the pulse, says David Epstein, who joined Flagship as an executive partner in 2017 after having been CEO of Novartis Pharmaceuticals. [40], In November 2020, Afeyan confirmed that the Canadian government had been among the first countries to pre-order the Moderna vaccine; the country is guaranteed to get some portion of the first batch dispensed to the public. The lengthy and very resource-intensive regulatory approval process to bring drugs or diagnostics to market has been a gating factor, along with the costly and often specialized process of then manufacturing these products at scale once approved. The firm has "fostered the development of more than 100 scientific ventures, resulting in $20 billion in total value and over 500 patents. In the world of computation, programming means giving a computer a set of instructions to conduct a set of calculations or tasks, yielding a very predictable and expected result. When buying cowboy boots, there are a few aspects to consider, such as how far up they go on your legs and their design. But public market performance doesnt tell the whole story of the hunt for value in biotech, or even the most interesting part. We have a history of emerging from major global crises with new global paradigms, and new institutions to support them. While we read official numbers like 5.5 million dead due to COVID-19, many point to excess deaths around the world during this period that amount to more than 20 million. Woman accused of fatally stabbing her mother in O.C. Linkedin Noubar Afeyan is founder, Senior Managing Partner and CEO of Flagship Ventures, a leading early stage venture capital firm. With the new capital, Flagship is ramping up its investments in therapeutics, agriculture and nutrition. If you see an error in this story, contact us. In July, Ring raised $117 million, bringing in T. Rowe Price among other investors. COVID-19 Accelerates Vaccine Manufacturing. day. As Covid-19 started to spread across China in early 2020, Noubar Afeyan, chair of Moderna, received a telephone call.It was his chief executive telling him that senior public health officials had . Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Each began life as little more than an idea in a lab. Noubar Afeyan is founder and CEO of Flagship Pioneering. Lord Ara Darzi, the leader of our Preemptive Health and Health Security Initiative, explains in this piece written with Flagships Tom Kibasi:New tools are being developed that will enable individuals to manage their own health by providing them with AI-enabled applications to assess their health status and determine if preemptive medicine interventions may be beneficial to avoid progression to a chronic disease. During the Armenian genocide of 1915-16, in which as many as 1.2 million Armenian. life sciences innovation firm Flagship Pioneering. After attending college, Afeyan came to the United States and earned a Ph.D. in biochemical engineering at the Massachusetts Institute of Technology (MIT). PerSeptive developed leading-edge technology in protein analysis, and grew to $100 million in revenue before Afeyan, sold it to scientific instruments conglomerate Perkin-Elmer for $360 million in 1998. The crystal trophy presented to him was inscribed with the words: "More things are wrought by prayer than this world dreams of." In a piece published by my colleagues Doug Cole and Christopher Austin, both physician-scientists, they issue a clarion call to improve health for millions: It is time for biotechnology companies to tackle the common illnesses that most people suffer from by determining the diseases that cause them. As a result, we can start to think of drugs as instructions or programs that have predictable outcomes and vice versa, we can envision an outcome, and then design the right program to achieve it. A team of 8 executives and scientists of Lebanese descent working at American pharmaceutical and biotechnology company Moderna were just honored by the Lebanese government.. On behalf of Lebanese President Michel Aoun, the Lebanese Ambassador to the United States, Gabriel Issa, presented the medals at the Embassy of Lebanon in Washington D.C. in a virtual ceremony that was just live-streamed . The underlying cause of most autoimmune diseases is related to T-cell misbehavior, Cox explains. [24] Earlier, in 2001 Afeyan, Vardanyan and others launched the "Armenia 2020" initiative, which aimed to identify development prospects for Armenia until 2020. How does one describe someone who has helped found 38 companies? [10], Besides English, Afeyan speaks Western Armenian. He is a Senior Lecturer at the MIT Sloan School of Management. Noubar Afeyan, co-founder and chairman ofModerna, is a two-time immigrant. First reported on December 12, 2019, we seem trapped in a never-ending year now in its 758th
That's very different than [the idea that] people ought to innovate and come up with . Programmable medicines are part of a larger transformative force that is already being felt: digital biology or the conversion of physical matter into information. Reflects change since 5 pm ET of prior trading day. Public market investors nonetheless remain biased toward single-asset biotechs. Between 2000 and 2005 the firm produced an average of two companies a year. Afeyan, an Armenian entrepreneur who was born in Lebanon and left the country with his family during its civil war, credits his background as an immigrant in his success and encourages others to . Noubar Afeyan (born July 25, 1962), is an American entrepreneur, venture capitalist, inventor, technologist, and CEO. He and his colleagues were looking for a way to deploy the messenger RNA molecule to tackle life-threatening. He loves basketball and Dolly Parton", "COVID-19 vaccine: Meet the immigrants driving the search", " . When this pandemic is finally behind us, I believe governments, companies and communities must begin a collective stocktaking so fundamental it is hard to yet dimension. In 2000, Afeyan founded Flagship Pioneering to create and fund early-stage start-ups addressing unmet needs in healthcare and sustainability. Moderna has a $1.525 billion contract to provide the United States with 100 million doses of the vaccine throughOperation Warp Speed, the governments fast-track program for Covid-19 vaccines, therapeutics, and diagnostics. There he oversaw the creation of Celera Genomics. We hope that we will have sometime in December the approval to go ahead and start getting the first doses out in the U.S. as well as hopefully in Europe, Afeyan said. He is also co-founder and Board Chairman of Moderna. What will emerge from the shocks and dislocations, the inventions and innovations, the losses and the lessons of the past 24 months? A recent article in Boston Business Journal listed the top 10 biotech investment rounds in the Boston area in 2021: the average raised was $397 million. A chance meeting with Hewlett-Packard cofounder David Packard at a National Science Foundation event in Washington, D.C., in 1985 left its mark. [5] Flagship Pioneering focuses on creating and investing in first-in-category, high-value life science companies in three principal business sectors: therapeutics, health technologies and sustainability. The European Medicines Agency announced Monday that it has begun a rolling review of the Moderna vaccine. Since December of 2020, the Food and Drug Administration, World Health Organization, and other regulatory bodies have authorized for emergency use or approved for commercial distribution at least two dozen vaccines and therapeutics for COVID-19, as well as numerous tests. However, Afeyan gained permanent residence through another route and is credited as a founder or co-founder of 38 companies. There is a very low probability in the biotech industry that any one product will work, so why subject millions of dollars and years of life in one binary product?, he says. [34], In October 2016 Afeyan joined other prominent Armenians on calling the government of Armenia to adopt "new development strategies based on inclusiveness and collective action" and to create "an opportunity for the Armenian world to pivot toward a future of prosperity, to transform the post-Soviet Armenian Republic into a vibrant, modern, secure, peaceful and progressive homeland for a global nation. (Read full essay here). Noubar Afeyan, an Armenian immigrant from Lebanon and grandson of a genocide survivor, is leading some of the breakthrough U.S. COVID-19 vaccine efforts as co-founder and chairman of Moderna. During the Armenian genocide of 1915-16, in which as many as 1.2 million Armenian Christians living in the Ottoman Empire were killed, Afeyans paternal grandfather and great uncle were taken away twice, he says. And, its not like the traditional flu shot. Jobs at Flagship Pioneering and our Companies. He has been a Senior Lecturer at MIT's Sloan School of . Noubar Afeyan Founder and CEO, Flagship Pioneering. In biotech and VC, people were saying, the era of biotech is over, the era of the platform is over. He is best known for co-founding the biotechnology company Moderna, through his venture capital firm, Flagship Pioneering, and for co-founding humanitarian projects such as Aurora Prize and The Future Armenian.As of November 2021, his net worth is . Noubar Afeyan, Founder and CEO, Flagship Pioneering speaks with Bloomberg's Shery Ahn at the Qatar Economic Forum, powered by Bloomberg. Years later, as the Communist regime took over Bulgaria, the Afeyans moved again, escaping to Greece before settling in Lebanon in the early-1950s. We have learned that none of that has worked, recalls Doug Cole, a medical doctor and Flagships managing partner who joined Afeyan as one of the first employees in 2001. As Moderna shares plunge below $50 in Wednesday morning trading, I called back to my Forbes article of last week. Zaks earned an M.D. In 2000, Afeyan founded Flagship Pioneering to create and fund early-stage start-ups addressing unmet needs in healthcare and sustainability. The answer is up to us. They said, How can anyone give you money? The vaccine was developed two days after [publication of the coronaviruss genomic] sequence. So far, 30 of Afeyans companies have completed the entire process. Noubar Afeyan (born July 25, 1962), is an American entrepreneur, venture capitalist, inventor, technologist, and CEO. The shares were sold at an average price of $173.17, for a total value of $1,731,700.00. Founded in 2000, Flagship is an enterprise where entrepreneurially-minded scientists invent seemingly unreasonable solutions to challenges If you see an error in this story, contact us. Noubar Afeyan (Western Armenian: ; born in 1962) is an American-Canadian entrepreneur, inventor, and philanthropist. Weve always believed that multiproduct bioplatform companies are most likely to create exponential potential. This article "Noubar Afeyan" is from Wikipedia. With $17 billion and a model of parallel entrepreneurship, he can fund a lot of wild notions. in the middle. An RNA vaccine essentially turns your body into its own vaccine manufacturing unit., In late April, Moderna requested permission from the Food and Drug Administration to move to a second phase of testing. life sciences innovation firm Flagship Pioneering. [15], Since 2000, Afeyan has been teaching courses on entrepreneurship, innovation and leadership at the Massachusetts Institute of Technologys Sloan School of Management. If you use a windshield cover, you can at least forget about scrapping the ice off your windshield to save some time and hassle. [1] He has patented over 100 inventions. A startup visa is one way. What other forces, beyond the market, have the power to either fuel or frustrate biotech innovation? Take, for example, the burgeoning applications of machine learning (ML) and artificial intelligence (AI) to biology. Afeyan wondered if a safe virus could replace the existing viruses in that role. If the idea proves promising enough, Flagship invests, and it operates for a time as a wholly owned subsidiary. Noubar Afeyan . Moderna founders debut on Forbes' list of 400 richest Americans. From 2007 to 2010, he also served on Boston Universitys Board of Overseers. [11] Afeyan is married to Anna (born Gunnardottir), a Swedish-born engineer who moved to the US in 1988. All Rights Reserved. Both Damiani and Andres have extensive international business experience. Thats a classically big idea for Afeyan, and Repertoire has now raised more than $350 million from investors that include SoftBank and the Alaska Permanent Fund to pursue it. Noubar Afeyan is founder, Senior Managing Partner and CEO of Flagship Pioneering, a leading innovation and early-stage venture capital firm. Moderna chairman Noubar Afeyan, whose estimated net worth is $3.7 billion, is . Like other Flagship companies, its also a so-called platform company, something that Afeyan argues reduces the risk of the startups in its portfolio and allows any of them to shift from one area to another as the need arises, as Moderna did with Covid-19 vaccines. It has since been expanded to 2031. 1998 - 2023 Nexstar Media Inc. | All Rights Reserved. And what if, he asked a decade ago, messenger RNA (mRNA) could be the basis of therapeutics? To alert special friends and family please email the link to this article. Through his work as an entrepreneur both before and at Flagship Pioneering, Afeyan has founded or helped start numerous companies, including Affinnova, Adnexus (acquired by Bristol Myers Squibb), BG Medicine, BIND Therapeutics, Celexion, Eleven Biotherapeutics, Ensemble Therapeutics, Joule Unlimited, LS9, Midori, Moderna Therapeutics, Permeon Biologics, Pronutria Biosciences (later renamed Axcella Health[7]) and Seres Therapeutics. [32][15][2], a founding angel of Foundation for Armenian Science and Technology (FAST).